6,14-Dimethyl-12,17-dioxatetracyclo[8.7.0.02,7.011,15]heptadeca-1(10),2,4,6,8,11(15)-hexaen-16-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6,14-Dimethyl-12,17-dioxatetracyclo[8.7.0.02,7.011,15]heptadeca-1(10),2,4,6,8,11(15)-hexaen-16-one
• 英文别名: 6,14-dimethyl-12,17-dioxatetracyclo[8.7.0.02,7.011,15]heptadeca-1(10),2,4,6,8,11(15)-hexaen-16-one
• 化学式: C₁₇H₁₄O₃
• 分子量: 266.29
• InChiKey: ZWWLADNULPMMGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• ATF3 induction compounds
  申请人：TAIPEI MEDICAL UNIVERSITY

  公开号：US11365200B2

  公开（公告）日：2022-06-21

  The invention relates to compounds for treating and/or preventing obesity and obesity-related disorders. Particularly, the invention provides chromanone derivatives used as ATF3 inducer and for treating and/or preventing obesity and obesity-related disorders such as heart disease, hypertension, hyperlipidemia and diabetes.

  本发明涉及用于治疗和/或预防肥胖和肥胖相关疾病的化合物。特别是，本发明提供了用作 ATF3 诱导剂和用于治疗和/或预防肥胖及肥胖相关疾病（如心脏病、高血压、高脂血症和糖尿病）的色原酮衍生物。
• ATF3 INDUCTION COMPOUNDS
  申请人：TAIPEI MEDICAL UNIVERSITY

  公开号：US20200361950A1

  公开（公告）日：2020-11-19

  The invention relates to compounds for treating and/or preventing obesity and obesity-related disorders. Particularly, the invention provides chromanone derivatives used as ATF3 inducer and for treating and/or preventing obesity and obesity-related disorders such as heart disease, hypertension, hyperlipidemia and diabetes.